Home

Current Clinical Trials

  • Children of Parents with Alzheimer's Needed for Research on Brain Structure/Function

    January 03, 2017

    Children of parents with alzheimer's are needed for research on brain structure/function. To be eligible individuals must be between the ages of 40 and 60, have a mother or father diagnosed with dementia/Alzheimer's after age 60, not be currently exercising, be willing to exercise 3 times per week for 6 months at Hartford Hospital, and be willing to undergo an MRI scan.

  • Healthy Volunteers Needed for Neuroimaging (Brain Scan) Study

    January 03, 2017

    Investigators at The Anxiety Disorders Center at the Institute of Living/Hartford Hospital are recruiting participants without psychiatric problems for a neuroimaging (brain scan) study. We are offering a study that involves undergoing a neuroimaging (brain) scan while also participating in tasks that will examine your brain functioning.

  • Research Volunteers Wanted to Examine Vascular Function in Testicular and Hodgkins Cancer Survivors

    January 03, 2017

    Research volunteers are wanted for examination of vascular function in testicular and Hodgkins cancer survivors. Participants must be 20-55 year old men previously treated for testicular cancer to be eligible. Participants who finish the study will receive free health information and financial compensation for their time.

  • Gynecologic Cancer (HIPEC) 12-275

    January 03, 2017

    This clinical trial aims to determine the most effective method for fighting gynecologic cancer. Patients who have had a first recurrence of ovarian, fallopian tube, or primary peritoneal cancer that initially responded to platinum-based therapy and which returned more than 6 and less than 30 months after completing that therapy are eligible for this study.

  • Targeted Teachable Moment Intervention Study

    January 03, 2017

    Targeted Teachable Moment Intervention Study

  • Breast Cancer 140124

    January 03, 2017

    This is an advanced Phase II study of various drugs to treat a metastatic form of breast cancer that produces the HER2 protein which provides messaging to cancer cells encouraging them to grow. Patients must be women with metastatic HER2-positive breast cancer who were previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine.

  • Bladder Cancer 15-291

    January 03, 2017

    Bladder cancers that invade the muscle wall of the bladder have a high risk of returning. Patients with these cancers typically have their bladders removed and are then monitored to see if the cancer comes back. In this study, researchers want to see if the drug atezolizumab can reduce the risk of cancer recurrence after bladder removal surgery for muscle-invasive bladder cancer.

  • Head/Neck Cancer 15-245

    January 03, 2017

    The treatment of head and neck cancers can sometimes leave survivors with problems such as dry mouth, difficulty swallowing, or other long-term side effects that may affect their quality of life. Researchers are interested in learning more about how survivors of head and neck cancers feel after their treatment is completed.

  • Participants Needed for Sickle Cell/Brain fMRI Research Study

    January 04, 2017

    This research study intends to understand how pain affects the brains of people with sickle cell disease. Healthy volunteers who are African-American and between the ages of 15-30 years are eligible. One 3-hour visit will be required and you will be compensated for your time!

  • Ketamine for Treatment-Resistant Depression

    January 04, 2017

    This clinical research study is being conducted to evaluate an investigational medication for treatment-resistant depression. We are currently enrolling patients for a clinical research study to look at the effectiveness and dosing requirements of an investigational medication that may help with the symptoms of depression.

  • Clinical Research Study on Pediatric and Adolescent Depression is Now Enrolling Participants

    January 04, 2017

    Does your child have depression? If so, s/he may be eligible to participate in a new research study being conducted by Dr. Salma Malik testing the effects of Vilazodone for the treatment of Depression. Participants must be 7 to 17 years of age and generally healthy.

  • Researchers seeking adolescents with and without ADHD, ages 9-18

    January 04, 2017

    The Olin Neuropsychiatry Research Center at The Institute of Living is conducting a study of adolescents with ADHD ages 9-18 and healthy adolescents ages 9-18 to look at how the brain functions during decision-making in cognitive tasks. The study will require at least 1 visit to complete interviews with clinical staff and MRI scans. Qualified volunteers will be compensated $20 per hour for participation.

  • Researchers Seeking Adults with Autism Spectrum Disorders, Ages 18-40

    January 04, 2017

    The Olin Neuropsychiatry Research Center at The IOL is conducting a study of adults with autism spectrum disorders (ASD) ages 18-40 to look at how our brains process social interactions and how it is different in individuals with ASD. The study may require two or more visits to complete interviews with clinical staff, MRI scans and an EEG. Qualified volunteers are compensated $20/hour for their time.

  • Researchers Seeking Participants for an Adult Depression Observational Study

    January 04, 2017

    The Burlingame Research Center at The Institute of Living is conducting a study on patients ages 18-64 that are currently taking an anti-depressant and responding to this therapy. This study will last up to 12 months and financial compensation for time and travel may be provided.

  • Healthy Adults Sought For Research Study

    January 04, 2017

    The Olin Neuropsychiatry Research Center at The Institute of Living is looking for healthy adults 18-60 with no significant history of mental illness. Participation will include: interviews and questionnaires, pencil and computer games, and an MRI. Qualifying persons will be compensated $20 per hour for their time. Lunch provided.

  • Participants with a Family History of Alcoholism Needed for Research Study

    January 04, 2017

    Are you a healthy, right-handed adult between the ages of 18 and 35? You may qualify to participate in a research study at The Olin Neuropsychiatry Research Center at the IOL. Individuals matching that description who have relatives with alcoholism or a history of alcoholism are eligible to participate in this research study.

  • Depression in Pediatric and Adolescents

    January 06, 2017

    The Burlingame Center for Psychiatric Research and Education is currently recruiting patients 7-17 years of age for a double-blind, clinical trial using Vilazodone for the treatment of pediatric and adolescent major depressive disorder. After completion of the 8-week study, subjects are eligible for a 6-month open-label trial of Vilazodone.

  • Sertraline Pediatric Registry (SPRITES)

    January 06, 2017

    This non-interventional study will examine the risks and benefits of up to 3 years of treatment with sertraline on cognition, emotional and physical development, and pubertal maturation in children ages 6 to 14 years. Recruitment Needs: Patients ages 6-14 diagnosed with an anxiety or depressive disorder that are starting sertraline or starting therapy but not taking sertraline, with an IOL psychiatrist or psychologist. This study will not alter treatment regimen.

  • Esketamine Research Study for Depression

    February 07, 2017

    Investigators at the Clinical Trials Unit of the Burlingame Center at the Institute of Living/Hartford Hospital are currently enrolling participants in a clinical research study for patients with depression who have not responded to prior treatment with an antidepressant. We will look at the effectiveness of an investigational nasal spray medication in delaying the return of depression symptoms in these patients.

  • Research Study for Adults Treated for Depression

    February 07, 2017

    The purpose of this study is to compare the accuracy and reliability of self-administered memory and thinking skills tests taken on an iPad tablet against the same tests administered by a doctor. The method for administering these tests could be used in future clinical studies when a study medication is being researched.

  • Research Study Seeking Healthy Volunteers

    February 07, 2017

    The purpose of this study is to compare the accuracy and reliability of self-administered memory and thinking skills tests taken on an iPad tablet against the same tests administered by a doctor. No investigational medicine or other medication will be used in the study.

  • Help for Hoarding at No Cost

    February 07, 2017

    The Anxiety Disorders Center at the Institute of Living/Hartford Hospital is conducting a study for people with Hoarding Disorder.

  • Healthy Volunteers Needed for Research Study

    February 07, 2017

    The Anxiety Disorders Center at the Institute of Living/Hartford Hospital is recruiting participants with no current or lifetime history of psychiatric problems for a research study.

  • Breast Cancer 16-073 PALLAS

    February 08, 2017

    A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

  • Gynecologic Cancer (Negative Pressure Wound Therapy in Post-Operative Incision Management) 15-309

    February 08, 2017

    The purpose of this study is to compare any good and bad effects of using the Prevena Incision Management System to using the usual standard dry gauze approach. The Prevena Incision Management System is a type of Negative Pressure Wound Therapy (NPWT). NPWT is a portable vacuum device made of a sponge-like foam that is applied over your incision to help draw fluid and debris out after surgery.

  • Breast Cancer 15-307

    February 08, 2017

    Feasibility study of adjuvant enzalutamide for the treatment of early stage AR(+) triple negative breast cancer.

  • Breast Cancer B-51

    April 10, 2017

    This trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have already undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer.

  • Gastric Cancer GS-US-296-1080

    April 11, 2017

    The primary objective of this study is to compare the efficacy of GS-5745 versus placebo in combination with modified Fluorouracil (5-FU), Leucovorin (LV), and Oxaliplatin (OXA) (mFOLFOX6) as measured by overall survival.

  • Bladder Cancer CA-ALT-803-01-14

    April 11, 2017

    The purpose of this study is to evaluate the safety, identify the Maximum Tolerated Dose (MTD) of ALT-803 and determine the Recommended Dose (RD) level of ALT-803 combined with BCG in patients who have nonmuscle invasive bladder cancer. The anti-tumor activity of BCG+ALT-803 will also be assessed. In addition, the study will characterize the molecular, immunogenicity and pharmacokinetic profile of BCG+ALT-803.

  • Urinary Cancer MK-3475-361

    April 11, 2017

    The purpose of this study is to determine the efficacy and safety of Pembrolizumab (MK-3475) with or without chemotherapy versus chemotherapy alone. The study is for participants with advanced (infiltrating the musculature) or metastatic (the development of secondary malignant growths at a distance from a primary site of cancer) urothelial carcinoma/bladder cancer.

  • Prostate Cancer S1216

    April 11, 2017

    This trial studies androgen deprivation therapy and Orteronel to see how well it works compared to androgen deprivation therapy and Bicalutamide, in treating patients with newly diagnosed prostate cancer that has spread to other places in the body.

  • Prostate Cancer SP005

    April 11, 2017

    The purpose of this study is to determine whether DCVAC/PCa (a new Active Cellular Immunotherapy medicinal product) added onto Standard of Care Chemotherapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer (advanced).

  • Colorectal Cancer NRG GI-002

    April 11, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety) trial studies how well Veliparib works with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started, to nearby tissue or lymph nodes (locally advanced).

  • Colorectal Cancer N1048/RTOG 1271

    April 11, 2017

    The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy. The study uses a combination regimen known as FOLFOX, (the drugs 5-Fluorouracil (5-FU), Oxaliplatin and Leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal cancer.

  • Pancreatic Cancer PCYC-1137-CA

    April 11, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II/III trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety. Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) to evaluate the efficacy of Ibrutinib in combination with Nab-Paclitaxel and Gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma (the development of secondary malignant growths at a distance from the primary site of cancer).

  • Pancreatic Cancer RTOG 0848

    April 11, 2017

    This trial studies Gemcitabine Hydrochloride with or without Erlotinib Hydrochloride, followed by the same chemotherapy regimen with or without radiation therapy, and Capecitabine or Fluorouracil in treating patients with pancreatic cancer that was removed by surgery. Chemotherapy drugs used, such as Gemcitabine Hydrochloride, Capecitabine, and Fluorouracil, work in different ways to stop the growth of tumor cells. The drugs work either by killing the cells, stopping them from dividing, or by stopping them from spreading.

  • Breast Cancer 673-301

    April 11, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this open-label, 2:1 randomized phase III trial (Phase III trials are new treatments that have worked well in a small number of patients with this disease) is to compare the safety and efficacy of Talazoparib (also known as BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and/or metastatic breast cancer (breast cancer that has spread beyond the breast to the chest wall or the skin of the breast, or to many lymph nodes in the underarm area, or to other organs ) with germline BRCA mutations.

  • Breast Cancer CDX-011 (METRIC)

    April 11, 2017

    The main purpose of this study is to see whether CDX-011 (Glembatumumab Vedotin, a monoclonal antibody-drug conjugate. Designed to harness the targeting ability of monoclonal antibodies by linking them to cell-killing agents) is effective in treating patients who have advanced Triple-Negative Breast Cancer (triple negative breast cancer diagnosis means that the tumor is estrogen receptor-negative, progesterone receptor-negative and HER2-negative), and whose tumor cells make a protein called glycoprotein NMB (gpNMB), which CDX-011 binds to. Estrogen and progesterone receptors are receptors that may be found in breast cancer cells. Her-2 is an oncogene, a gene that has the potential to cause cancer. The study will also further characterize the safety of CDX-011 treatment in this patient population.

  • Breast Cancer ECOG E2112

    April 11, 2017

    High amounts of estrogen (primary female hormone) can cause the growth of breast cancer cells. Endocrine/Hormone therapy using Exemestane may fight breast cancer by lowering the amount of estrogen the body makes or interferes with the effects. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether Exemestane is more effective with or without Entinostat in treating breast cancer.

  • Breast Cancer BR003

    April 11, 2017

    Estrogen receptors and progesterone receptors are receptors that may be found in breast cancer cells. Drugs used in chemotherapy, such as Doxorubicin Hydrochloride, Cyclophosphamide, Paclitaxel, and Carboplatin, work in different ways to stop the growth of tumor cells. They work either by killing the cells, stopping cells from dividing, or by stopping cells from spreading. It is not yet known whether Doxorubicin Hydrochloride and Cyclophosphamide is more effective when followed by Paclitaxel alone or Paclitaxel and Carboplatin in treating triple-negative breast cancer.

  • Breast Cancer SWOG S1207

    April 11, 2017

    High amounts of estrogen (primary female hormone) can cause the growth of breast cancer cells. Hormone therapy using certain treatments may fight breast cancer, by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether hormone therapy is more effective when given with or without Everolimus in treating breast cancer.

  • PULSE Pilot Study

    April 13, 2017

    The Department of Preventive Cardiology is seeking individuals with high blood pressure for an exercise training study. You may qualify if you have (or think you have) high blood pressure; 18 years or older; non-smoker; and currently exercise less than two days per week.

  • Hematological CC-486-AML-001

    April 26, 2017

    This study will enroll approximately 460 subjects, aged 55 or older, with a diagnosis of de novo AML (Acute Myeloid Leukemia) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (CMML), and who have achieved first complete remission.

  • Gastrointestinal Cancer 3475-181

    April 26, 2017

    This study focuses on treating patients who have undergone surgery for head and neck cancer that has spread to nearby tissues or organs.

  • Head/Neck Cancer 0920

    April 26, 2017

    This study focuses on treating patients who have undergone surgery for head and neck cancer that has spread to nearby tissues or organs.

  • Gynecologic Cancer 286B

    April 26, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II/III trial studies how well Paclitaxel, Carboplatin, and Metformin Hydrochloride works and compares it to Paclitaxel, Carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back.

  • Gynecologic Cancer NRG-005

    April 26, 2017

    This trial studies how well Cediranib Maleate and Olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).

  • Gynecologic Cancer NRG-004

    April 26, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial that studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Phase III trials are new treatments that have worked well in a small number of patients with a disease.

  • Gynecologic Cancer D0816C00010-SOLO 3

    April 26, 2017

    This study is for patients with germline Breast Cancer susceptibility gene (gBRCA) mutated ovarian cancer who have progressed at least 6 months after the last platinum based chemotherapy.

  • Gynecologic Cancer GOG 281

    April 26, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II/III trial that studies how well Trametinib works and compares it to standard treatment with either Letrozole, Tamoxifen citrate, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, or Topotecan hydrochloride in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back, become worse, or spread to other parts of the body.

  • Gynecologic Cancer ET743-OVC-3006

    April 26, 2017

    The purpose of this study is to assess the efficacy and safety of Trabectedin+DOXIL as a third-line chemotherapy regimen in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.

  • Gynecologic Cancer 3005/ABBVIE M13-694

    April 26, 2017

    The focus of this study is to evaluate the efficacy, safety, and tolerability of Veliparib in women with previously untreated, Stage III or IV (cancer which has spread from the site of the primary (original) tumor only to surrounding tissue, lymph nodes, or the development of secondary malignant growths at a distance from a primary site of cancer), high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  • Gynecologic Cancer 264

    April 26, 2017

    This trial studies Paclitaxel and Carboplatin to see how well they work compared with Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in treating patients with sex cord-ovarian stromal tumors (gastrointestinal) that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has returned (recurrent).

  • Gynecologic Cancer 274

    April 26, 2017

    This trial studies how well giving Cisplatin and radiation therapy together with or without Carboplatin and Paclitaxel works in treating patients with cervical cancer has spread from where it started to nearby tissue or lymph nodes.

  • Gastric Cancer EMR100070-007

    April 26, 2017

    The purpose of this study is to demonstrate superiority of treatment with Avelumab (an immunotherapy drug) versus continuation of first-line chemotherapy.

  • Lung Cancer E4512

    April 27, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial (Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) that studies how well Crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK).

  • Lung Cancer Alchemist A081105

    April 27, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III (Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) trial that studies how well Erlotinib Hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery.

  • Lung Cancer Alchemist A151216

    April 27, 2017

    This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been, or will be removed by surgery.

  • Melanoma EA6134

    April 27, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial (Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) which studies how well initial treatment with Ipilimumab and Nivolumab followed by Dabrafenib and Trametinib works and compares it to initial treatment with Dabrafenib and Trametinib followed by Ipilimumab and Nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery.

  • Melanoma ECOG3612

    April 27, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety) which studies how well Ipilimumab with or without Bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.

  • Myeloma CC-4047-MM-007

    April 27, 2017

    The purpose of this study is to compare the efficacy of the combination of Pomalidomide, Bortezomib and Dexamethasone to the combination of Bortezomib and Dexamethasone in patients with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of Pomalidomide, Bortezomib and Dexamethasone is compared to the combination of Bortezomib and Dexamethasone.

  • Myeloma E3A06

    April 27, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II/III trial which studies how well Lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk asymptomatic (smoldering, an early precursor to blood cancer) multiple myeloma.

  • Lymphoma B3281006

    April 27, 2017

    This study will compare the safety and effectiveness of PF-05280586 versus Rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma.

  • Lung Cancer EA5142

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial that studies how well Nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.

  • Lung Cancer CA209370

    May 09, 2017

    The purpose of this study is to determine whether Nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.

  • Lung Cancer GO29537

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this Phase III, multicenter, open-label study which is designed to evaluate the safety and efficacy of Atezolizumab (MPDL3280A) in combination with Carboplatin + Nab-Paclitaxel compared with treatment with Carboplatin + Nab-Paclitaxel in chemotherapy-naive patients with Stage IV non-squamous non-small cell lung cancer (NSCLC).

  • Lung Cancer GO29527

    May 09, 2017

    This study is for participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC). Eligible patients who enroll in the study will be randomly assigned (by chance) to this Phase III, global, multicenter, open-label, study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of Atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC).

  • Lung Cancer RTOG-1306

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety) studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer.

  • Lung Cancer SWOG-1400

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this screening and multi-sub-study phase II/III trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

  • Lung Cancer 20070782

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this double-blind, placebo-controlled phase 3 non-inferiority study in subjects with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV.

  • Lung Cancer B7391003

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned to this multinational, double-blind, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of Bevacizumab-Pfizer plus Paclitaxel and Carboplatin versus Bevacizumab-EU plus Paclitaxel and Carboplatin in first-line treatment for patients with advanced non-squamous NSCLC.

  • Localized Spine Metastasis 0631

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned to this phase II/III trial studying how well image-guided radiosurgery or stereotactic body radiation therapy works and compares it to external-beam radiation therapy in treating patients with localized spine metastasis.

  • Castration-Resistant Prostate Cancer (Trumpet-ONC-MA-1004)

    May 09, 2017

    The purpose of this study is to describe patterns of care in CRPC (Castration-Resistant Prostate Cancer) patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management.

  • Venous Thromboembolism (VTE) 39039039STM4001 (BAY 59-7939)

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned to this multicenter, double-blind, placebo-controlled, parallel-group, superiority study comparing the efficacy and safety of Rivaroxaban with placebo for primary prophylaxis of venous thromboembolism (VTE) in ambulatory adult participants, with various cancer types who are scheduled to initiate systemic cancer therapy.

  • Solid Tumors/Lymphomas

    May 09, 2017

    This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.

  • Metastatic/Locally Advanced Solid Tumors EMR200647-001

    May 09, 2017

    The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks in patients with metastatic or locally advanced solid tumors.

  • Bio Specimens (GRAIL)

    May 09, 2017

    This is a prospective, multi-center, observational study with collection of de-identified bio specimens and clinical data from at least 10,000 participants from clinical networks in the United States.

  • Research Study Volunteers Needed!

    May 17, 2017

    Dr. Taylor from Hartford Hospital, Dr. Pescatello from the UConn Department of Kinesiology and Dr. Puhl from the UConn Rudd Center are conducting a research study tocompare the effects of a short-term encounter to media videos on measures of mental and physical heart health in women.

MSK_ClinicalTrials_Ad